JP2009525302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525302A5 JP2009525302A5 JP2008552778A JP2008552778A JP2009525302A5 JP 2009525302 A5 JP2009525302 A5 JP 2009525302A5 JP 2008552778 A JP2008552778 A JP 2008552778A JP 2008552778 A JP2008552778 A JP 2008552778A JP 2009525302 A5 JP2009525302 A5 JP 2009525302A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- integer
- ono
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- -1 2- (acetyloxy) benzoic acid 3- (nitrooxymethyl) phenyl ester Chemical class 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- 229960005370 atorvastatin Drugs 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 0 *C(CCC1)C1C1(C2CC2)C2(CC2)C1 Chemical compound *C(CCC1)C1C1(C2CC2)C2(CC2)C1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76475506P | 2006-02-03 | 2006-02-03 | |
| US60/764,755 | 2006-02-03 | ||
| PCT/EP2007/050630 WO2007088123A2 (en) | 2006-02-03 | 2007-01-23 | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009525302A JP2009525302A (ja) | 2009-07-09 |
| JP2009525302A5 true JP2009525302A5 (https=) | 2010-03-11 |
| JP5745210B2 JP5745210B2 (ja) | 2015-07-08 |
Family
ID=38004694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552778A Expired - Fee Related JP5745210B2 (ja) | 2006-02-03 | 2007-01-23 | 筋ジストロフィーの治療用薬剤のニトロオキシ誘導体の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8575222B2 (https=) |
| EP (2) | EP2786749A1 (https=) |
| JP (1) | JP5745210B2 (https=) |
| KR (1) | KR20080097989A (https=) |
| CN (1) | CN101378739B (https=) |
| AU (1) | AU2007211508B2 (https=) |
| CA (1) | CA2641816C (https=) |
| DK (1) | DK1978947T3 (https=) |
| ES (1) | ES2520893T3 (https=) |
| IL (1) | IL192299A0 (https=) |
| NZ (1) | NZ569396A (https=) |
| PL (1) | PL1978947T3 (https=) |
| PT (1) | PT1978947E (https=) |
| RU (2) | RU2560144C2 (https=) |
| SI (1) | SI1978947T1 (https=) |
| WO (1) | WO2007088123A2 (https=) |
| ZA (1) | ZA200805716B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2731298T3 (es) | 2005-05-27 | 2019-11-14 | Univ North Carolina Chapel Hill | Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas |
| CN103271935A (zh) | 2006-08-01 | 2013-09-04 | 普里克萨斯医药股份有限公司 | 泊洛沙姆用于预防和/或治疗心力衰竭的用途 |
| KR20090128423A (ko) * | 2007-04-13 | 2009-12-15 | 니콕스 에스. 에이. | 아토르바스타틴 4-(니트록시)부틸 에스테르의 결정형 |
| WO2009079562A2 (en) | 2007-12-17 | 2009-06-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing skeletal muscle deficiencies |
| EP2257340A2 (en) * | 2008-04-04 | 2010-12-08 | BioMarin IGA Limited | Compounds for treating muscular dystrophy |
| WO2010108843A1 (en) | 2009-03-27 | 2010-09-30 | Nicox S.A. | Use of nitrooxyderivative of paracetamol for the treatment of muscular dystrophies |
| CA2771389C (en) | 2009-08-21 | 2019-04-09 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| US9023890B2 (en) | 2009-12-02 | 2015-05-05 | The Charlotte-Mecklenburg Hospital Authority | Nitrate esters and their use for the treatment of muscle and muscle related diseases |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
| US9452117B2 (en) | 2011-06-01 | 2016-09-27 | The Charlotte-Mecklenburg Hospital Authority | Nitrate esters and their use for the treatment of muscle and muscle related diseases |
| CA2897571C (en) | 2013-01-21 | 2018-12-18 | Apparao Satyam | Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group |
| RU2517259C1 (ru) * | 2013-03-06 | 2014-05-27 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) | Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой |
| WO2014169976A1 (en) * | 2013-04-18 | 2014-10-23 | Nicox Science Ireland | Quinone based nitric oxide donating compounds |
| US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
| US10993993B2 (en) | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
| KR101661332B1 (ko) | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| JP7250810B2 (ja) | 2018-04-25 | 2023-04-03 | オンコクロス カンパニー，リミテッド | 筋肉疾患の予防及び治療用組成物 |
| US12263206B2 (en) | 2018-09-14 | 2025-04-01 | Medi&Gene Inc. | Pharmaceutical composition for preventing or treating obesity or sarcopenia, containing IF1 as active ingredient |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| KR102329853B1 (ko) | 2021-03-25 | 2021-11-23 | 주식회사 엔테로바이옴 | 아커만시아 뮤시니필라 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물 |
| KR102272616B1 (ko) | 2021-03-25 | 2021-07-05 | 주식회사 엔테로바이옴 | 피컬리박테리움 프로스니치 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0759899T1 (en) * | 1994-05-10 | 1999-12-31 | Nicox S.A. | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| US5583101A (en) * | 1994-07-15 | 1996-12-10 | Harvard College | Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction |
| IT1288123B1 (it) * | 1996-09-04 | 1998-09-10 | Nicox Sa | Uso di nitroderivati per l'incontinenza urinaria |
| WO2000053191A2 (en) * | 1999-03-11 | 2000-09-14 | The University Of Manitoba | Modulation of skeletal muscle precursor cell activation |
| FR2794647A1 (fr) * | 1999-06-11 | 2000-12-15 | Centre Nat Rech Scient | Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules |
| ITMI991517A1 (it) | 1999-07-09 | 2001-01-09 | Nicox Sa | Procedimento per ottenere nitrossimetil fenil esterni di derivati dell'acido salicilico |
| IT1313596B1 (it) * | 1999-08-04 | 2002-09-09 | Nicox Sa | Processo per la preparazione di nitrossialchil esteri del naproxene |
| ITMI20011744A1 (it) * | 2001-08-09 | 2003-02-09 | Nicox Sa | Farmaci per le vasculopatie |
| ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
| US7166638B2 (en) | 2003-05-27 | 2007-01-23 | Nicox S.A. | Statin derivatives |
| WO2005023189A2 (en) * | 2003-09-03 | 2005-03-17 | Pharmacia Corporation | Method of cox-2 selective inhibitor and nitric oxide-donating agent |
| GB0321228D0 (en) * | 2003-09-10 | 2003-10-08 | Inpharmatica Ltd | Modulating cell activity |
| US8106080B2 (en) * | 2005-06-09 | 2012-01-31 | Gu-Qi Wang | Compositions and methods for enhancing nitric oxide delivery |
| WO2007088050A2 (en) | 2006-02-03 | 2007-08-09 | San Raffaele Centro Fond | Method of treatment for muscular dystrophy |
-
2007
- 2007-01-23 EP EP20140175223 patent/EP2786749A1/en not_active Withdrawn
- 2007-01-23 WO PCT/EP2007/050630 patent/WO2007088123A2/en not_active Ceased
- 2007-01-23 DK DK07712084.8T patent/DK1978947T3/da active
- 2007-01-23 EP EP07712084.8A patent/EP1978947B1/en active Active
- 2007-01-23 PL PL07712084T patent/PL1978947T3/pl unknown
- 2007-01-23 RU RU2011118522/04A patent/RU2560144C2/ru not_active IP Right Cessation
- 2007-01-23 JP JP2008552778A patent/JP5745210B2/ja not_active Expired - Fee Related
- 2007-01-23 ES ES07712084.8T patent/ES2520893T3/es active Active
- 2007-01-23 NZ NZ569396A patent/NZ569396A/en not_active IP Right Cessation
- 2007-01-23 CN CN200780004219.7A patent/CN101378739B/zh not_active Expired - Fee Related
- 2007-01-23 SI SI200731542T patent/SI1978947T1/sl unknown
- 2007-01-23 AU AU2007211508A patent/AU2007211508B2/en not_active Ceased
- 2007-01-23 RU RU2008135153/15A patent/RU2429828C2/ru not_active IP Right Cessation
- 2007-01-23 US US12/159,577 patent/US8575222B2/en not_active Expired - Fee Related
- 2007-01-23 KR KR1020087015930A patent/KR20080097989A/ko not_active Ceased
- 2007-01-23 PT PT77120848T patent/PT1978947E/pt unknown
- 2007-01-23 CA CA2641816A patent/CA2641816C/en not_active Expired - Fee Related
-
2008
- 2008-06-19 IL IL192299A patent/IL192299A0/en unknown
- 2008-06-30 ZA ZA200805716A patent/ZA200805716B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525302A5 (https=) | ||
| RU2008135153A (ru) | Применение нитрооксипроизводного лекарственного средства для лечения мышечной дистрофии | |
| JP2010509379A5 (https=) | ||
| JP2010534247A5 (https=) | ||
| JP2009519993A5 (https=) | ||
| JP2008525416A5 (https=) | ||
| JP2007519721A5 (https=) | ||
| JP2010536766A5 (https=) | ||
| JP2010511721A5 (https=) | ||
| JP2018127459A5 (https=) | ||
| JP2011037841A5 (https=) | ||
| JP2011505347A5 (https=) | ||
| JP2012506896A5 (https=) | ||
| JP2018135343A5 (https=) | ||
| JP2010502730A5 (https=) | ||
| JP2011520815A5 (https=) | ||
| JP2009501198A5 (https=) | ||
| JP2009529540A5 (https=) | ||
| CA2407149A1 (en) | Melanin-concentrating hormone antagonist | |
| JP2011519910A5 (https=) | ||
| JP2004115534A5 (https=) | ||
| JP2013517322A5 (https=) | ||
| JP2009519226A5 (https=) | ||
| JP2014505017A5 (https=) | ||
| JP2008500999A5 (https=) |